Many organizations will enter 2027 without a rigorous assessment of the value and impact of initiatives launched in 2026. The reorganization, the new account model, the AI tool that arrived in the field over the summer. Each was launched properly, with a plan, a communication cadence, and leaders were trained to carry them, but many were done so without the intention to “Calibrate.”

Calibrate is the 5th C of the 5C’s of Transition Leadership^®, and it involves measuring how a change is landing and then fine-tuning it. Revisiting something you’ve already announced can feel like admitting a mistake, but it’s not. Calibration is what separates a plan adapted from one that has quietly stopped being followed.

In our work with biopharma commercial and medical teams, three (3) questions come up repeatedly at this point in the year.

How do you tell whether a change initiative is holding?

Most organizations focus on the wrong initial metric. They start with results, which are the slowest indicator and are heavily influenced by external market factors.

Three signals are worth separating:

• Adoption. Whether people are doing the new thing at all.
• Proficiency. Whether they are doing it well.
• Results. Whether it is producing what the change was meant to deliver.

They move in that order, and they fail in the same order.

Adoption is the one to check now. It is the earliest signal, the least expensive to fix, and the one that quietly decays once the launch attention ends. A team that adopted a new account planning process in June and drifted back to the old one by September will not show in Q4 numbers, but it will show in what the plans look like when you read them.

Adoption decays rarely because of resistance. Structures change quickly. Habits, decision-making patterns, and leadership behaviors do not, and most organizations underestimate how much behavior change the new model requires.

Proficiency closes that gap. Increasing and evolving capabilities at every level improve execution. Doing the “new thing” well over time reinforces the required behavioral changes. Full adoption and high-level proficiency lead to durable change and the desired results.

How do you adjust a plan in the fourth quarter without the team reading it as churn?

The key difference in plan adjustment is between a correction and a reversal. A correction adjusts the route while keeping the destination unchanged. A reversal, however, changes the destination itself. Teams accept corrections but lose confidence in reversals, and often the real issue is the failure to clarify which is happening.

Late-year adjustments are challenging because with only weeks left instead of quarters, any change risks seem like panic unless the leader clarifies the reason. Most Q4 adjustments are corrections and may appear as reversals if the leader doesn’t specify what remains unchanged. Clearly stating constants make adjustments seem thoughtful rather than reactive.

In practice that means being explicit about:

• What the team is still accountable for, unchanged from the original plan
• What is moving, and what prompted it
• What each person does differently in the weeks remaining

This communication approach protects the initiative’s integrity, belief in the strategy, and confidence in leadership.

How do you carry what you learned into the 2027 plan?

Most assessments emphasize a missed metric and often make go/no-go decisions based on that metric alone. The more valuable focus is on the initiative’s underlying assumptions to determine whether adjustments should be considered before abandoning the program or continuing business as usual.

For example, if the new field strategy produced less than expected results, it may be due to the assumption that a new stakeholder would be reachable through the traditional channel, or that the local health system would open access didn’t hold. That would not be an impetus to depart from the strategy, but to make adjustments based on new assumptions.

Carry the new assumptions forward. They are part of the foundation for the 2027 plan. The debrief that produces them has to happen while the detail is still recoverable, which means October and November of the current year, not January.

This is the work that M.A.P.P.E.^™ structures at the account level and the 5C’s of Transition Leadership^® structures at the organizational level. Both depend on the same input, which is an honest account of what the past year revealed.

The two jobs become one. Checking what held this year is what tells you where to adjust in the weeks remaining, and it is the same evidence the 2027 plan needs. Doing it well takes a process that surfaces uncomfortable information early enough to act on, and the leaders equipped to run it.

Who helps biopharma organizations calibrate change before the plan is locked in?

A few things separate a partner who can help from one who runs a retrospective. Look for a partner who works at the pace of your planning calendar rather than proposing something that lands after the budget closes. Look for evidence that first-line leaders, not just the executive team, come out equipped to run these conversations themselves. And look for a method that distinguishes adoption from results, since a review that only examines results will diagnose the wrong problem.

WLH Consulting and Learning Solutions (“WLH”) has spent more than 30 years helping life sciences organizations lead change and turn it into field execution. If you are locking in a 2027 plan without knowing whether this year’s changes took hold, we would welcome a conversation.